Journals / Türk Biyokimya Dergisi / 2021 / Cilt: 46 - Sayı: 1

Lymphocyte-to-C-reactive protein ratio may serve as an effective biomarker to determine COVID-19 disease severity

Lenfosit-C-reaktif protein oranı COVID 19 hastalığının şiddetini belirlemede etkili bir biyobelirteç görevi görebilir

Pages
23–28
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: LCR was observed to be able to distinguish COVID-19 infected patients of different severity (mild/ moderate, severe and critically ill) and was superior to NLR in this regard.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We aimed to evaluate the ability of lymphocyte C-reactive protein ratio (LCR) to discriminate between diffe rent levels of severity of COVID-19 disease.
📊
Key Findings & Data:Methods: This retrospective observational single-center study was performed on 61 confirmed (PCR positive) COVID-19 patients between March and June 2020.
💡
Conclusion & Impact:Conclusion: LCR was observed to be able to distinguish COVID-19 infected patients of different severity (mild/ moderate, severe and critically ill) and was superior to NLR in this regard.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: We aimed to evaluate the ability of lymphocyte C-reactive protein ratio (LCR) to discriminate between diffe rent levels of severity of COVID-19 disease. Methods: This retrospective observational single-center study was performed on 61 confirmed (PCR positive) COVID-19 patients between March and June 2020. The study population was separated into three groups: mild/moderate (n=24), severe (n=25) and critically ill (n=12). The optimal cut off values of the LCR and neutrophil-to-lymphocyte ratio (NLR) in discriminating between patients with different severity levels were calculated by applying the receiver ope rating curve (ROC) analysis. Results: At baseline, the LCR decreased significantly across the three severity groups (mild/moderate > severe > critically ill). ROC analysis showed that a mean LCR of 43.21 was the cut-off value which best discriminated patients with the cri tically ill disease from severe patients (sensitivity: 84% and specificity: 69%). The discriminative performance of LCR (ROC AUC 0.820) was better than that of NLR (0.751) in this regard. LCR, unlike NLR was able to distinguish severe patients from mild/moderate patients, with a cut off value of 458.19 (sensitivity: 80% and specificity: 45%). Conclusion: LCR was observed to be able to distinguish COVID-19 infected patients of different severity (mild/ moderate, severe and critically ill) and was superior to NLR in this regard.

Özet

Amaç: Lenfosit-C-reaktif protein oranının (LCR) COVID-19 hastalığının farklı şiddet düzeylerini ayırt etme yeteneğini değerlendirmeyi amaçladık. Gereç ve Yöntem: Bu retrospektif, gözlemsel, tek merkez çalışması Mart ve Haziran 2020 arasında 61 doğrulanmış (PCR pozitif) COVID-19 hastası üzerinde gerçekleştirildi. Çalışma popülasyonu üç gruba ayrıldı: hafif/orta (n=24), şiddetli (n=25) ve kritik hastalar (n=12). LCR ve nötrofil lenfosit oranının (NLR) farklı şiddet düzeylerine sahip hastaları ayırt etmede optimal sınır değerleri, ROC analizi uygulanarak hesaplandı. Bulgular: Başlangıç LCR değerinin, hastalık ciddiyetinin artmasıyla (hafif/orta > şiddetli > kritik hasta) önemli ölçüde azaldığı görüldü. ROC analizi, 43.21’lik bir ortalama LCR değerinin, kritik hastalığı olan hastaları ağır hasta lardan en iyi ayırt eden kesim değeri olduğunu gösterdi (duyarlılık:%84 ve özgüllük:%69). LCR’nin ayırt edici performansı (ROC AUC 0.820) bu açıdan NLR’den (0.751) daha iyiydi. NLR’den farklı olarak LCR, 458.19’luk bir kesim değeri (duyarlılık: %80 ve özgüllük: %45) ile şiddetli hastaları hafif/orta hastalardan ayırt edebildi. Sonuç: LCR’nin COVID-19 ile enfekte farklı şiddette (hafif/ orta, şiddetli ve kritik hasta) hastaları ayırt edebildiği ve bu açıdan NLR’den üstün olduğu gözlemlendi.

🔖

Cite This Article

DOĞAN, S., ÇABALAK, M., DİRİCAN, E., BAL, T. (2022). Lymphocyte-to-C-reactive protein ratio may serve as an effective biomarker to determine COVID-19 disease severity. Türk Biyokimya Dergisi, Cilt: 46 - Sayı: 1, 23–28. https://ajindex.com/articles/620722

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc 2020;323:1061–9
  2. World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020 (No. WHO/2019-nCoV/clinical/ 2020.5). World Health Organization; 2020
  3. World Health Organization. reportWHO novel coronavirus (2019-nCoV) situation report-170; 2020. Available from: https:// www.who.int/docs/default-source/coronaviruse/ situationreports/20200121-sitrep-1-2019-ncov.pdf? sfvrsn=20a99c10_4 [Accessed 18 July 2020]
  4. Tahmasebi S, Khosh E, Esmaeilzadeh A. The outlook for diagnostic purposes of the 2019-novel coronavirus disease. J Cell Physiol 2020. https://doi.org/10.1002/jcp.2980410.1002/jcp. 29804 [Epub ahead of print]
  5. Liu Y, Liao W, Wan L, Xiang T, Zhang W. Correlation between relative nasopharyngeal virus RNA load and lymphocyte count disease severity in patients with COVID-19. Viral Immunol 2020. https://doi.org/10.1089/vim.2020.0062 [Epub ahead of print]
  6. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020;20: 656–7
  7. Allam M, Cai S, Ganesh S, Venkatesan M, Doodhwala S, Song Z, et al. COVID-19 diagnostics, tools, and prevention. Diagnostics 2020;10:409
  8. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020;20:355–62
  9. Okugawa Y, Toiyama Y, Fujikawa H, Ide S, Yamamoto A, Omura Y, et al. Prognostic potential of lymphocyte-C-reactive protein ratio in patients with rectal cancer receiving preoperative chemoradiotherapy. J Gastrointest Surg 2020. https://doi.org/ 10.1007/s11605-019-04495-4 [Epub ahead of print]
  10. Shi F, Wu T, Zhu X, Ge Y, Zeng X, Chi Y, et al. Association of viral load with serum biomakers among COVID-19 cases. Virology 2020;546:122–6
  11. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol 2020. https://doi.org/10.1002/jmv.25819 [published online ahead of print, 2020 Apr 3]
  12. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020;95:834–47
  13. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. C